---
title: "Regeneron director Arthur F. Ryan sells 200 shares worth $130,030"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291971980.md"
description: "Regeneron Pharmaceuticals director Arthur F. Ryan sold 200 common shares on July 2, 2026, at $650.15 per share, totaling approximately $130,030. Following the transaction, his direct holdings decreased to 17,303 shares. The disclosure was filed via EDGAR on July 7, 2026."
datetime: "2026-07-07T20:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291971980.md)
  - [en](https://longbridge.com/en/news/291971980.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291971980.md)
---

# Regeneron director Arthur F. Ryan sells 200 shares worth $130,030

-   Regeneron director Arthur F. Ryan sold 200 common shares on July 2, 2026. \* Sale price USD 650.15 per share; direct holdings fell to 17,303 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001187443-26-000010), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS](https://longbridge.com/en/news/293393923.md)
- [Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN](https://longbridge.com/en/news/293102094.md)
- [Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer | MRK Stock News](https://longbridge.com/en/news/293648797.md)
- [RH files Form 3 for Chief Legal & Compliance Officer Ryan George Hassanein](https://longbridge.com/en/news/293668500.md)
- [Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statement](https://longbridge.com/en/news/293540204.md)